Sign in to view content

Early Fluid-Free Status & Long-Term BCVA Outcomes With Anti-VEGF Treatment in nAMD: Post Hoc Analysis of Pooled Data From HAWK & HARRIER Studies

Chirag D. Jhaveri, MD, FASRS

Video
Published 2020

Related

Prophylaxis Intravitreal Aflibercept Against Conversion to Neovascular AMD in High-Risk Eyes (PRO-CON): 24-Month Results
Jeffrey S. Heier, MD
Annual Meeting Talks
2019
Pharmacokinetic Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 3 Archway Trial
Peter A. Campochiaro, MD
Updates from the Field
2021
Real World Experience of Brolucizumab for Persistent Macular Fluid in Neovascular Age-Related Macular Degeneration After Prior Anti-VEGF Treatments
Rehan M. Hussain, MD
Annual Meeting Talks
2021

Category: AMD-Neovascular

See more